Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: A multi-centre, double-blind, randomized, placebo-controlled study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 4, 2010, Pages 516-528

  Zuberbier, T ^a   Oanta, A ^b   Bogacka, E ^c   Medina, I ^d   Wesel, F ^e   Uhl, P ^f   Antepara I ^g   Jauregui I ^g   Valiente, R ^a,h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b S C Dermamed SRL   (Romania)

^c NZOZ Materia Medica   (Poland)

^d Centro Medico Vitae   (Argentina)

^e Cabinet d'Allergologie   (France)

^f Arzt für Haut u Geschlechlskrankheiten Allergologie   (Germany)

^g HOSPITAL DE BASURTO   (Spain)

^h FAES FARMA SA   (Spain)

Author keywords

Bilastine; Chronic idiopathic urticaria; Dermatology Life Quality Index; H1antihistamine; Total symptoms score

Indexed keywords

ANTIHISTAMINIC AGENT; BILASTINE; LEVOCETIRIZINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GLAUCOMA; HEADACHE; HEART RATE; HUMAN; IDIOPATHIC DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; QUALITY OF LIFE INDEX; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URTICARIA;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BENZIMIDAZOLES; CETIRIZINE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; QUALITY OF LIFE; URTICARIA; YOUNG ADULT;

EID: 77649216982     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.02217.x     Document Type: Article

References (37)

1. Kozel MMA, Sabroe RA. Chronic Urticaria. Aetiology, management and current future treatment options. Drugs 2004 64 : 2515 2536.
2. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007 34 : 294 301.
3. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003 3 : 363 368.
4. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007 37 : 631 650.
5. 2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006 61 : 316 320.
6. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997 136 : 197 201.
7. 1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005 76 : 119 126.
8. 2LEN/EDF guideline: management of urticaria. Allergy 2006 61 : 321 331.
9. Faes Farma SA. Bilastine (F-96221-BMI): a novel antihistamine compound for the treatment of allergic rhinitis and chronic idiopathic urticaria. Investigational Drug Brochure (Version 9 July 2008). Data on file; http://www.faes.es (last accessed August 2009)
10. 1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005 6 : 371 384.
11. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006 7 : 219 231.
12. Sologuren A, Valiente R, Crean C, McLaverty A. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol 2007 47 : 1198 (abstract 69).
13. 14 C] bilastine. Drug Metabol Rev 2007 39 (Suppl. 1 114 (abstract 160).
14. 1 receptor antagonist. Drug Metabol Rev 2007 39 (Suppl. 1 200 201 (abstract 282).
15. Crean C, Roupe K, Sologuren A, Valiente R. The pharmacokinetics of bilastine after single and 14 days once daily administration. Basic Clin Pharmacol Toxicol 2007 101 (Suppl. 1 148.
16. 1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008 28 : 675 685.
17. Sologuren A, Valiente R, Allison M, Tyl B. Lack of significant effect of bilastine on ventricular repolarization. A thorough QT/QTc study. Allergy 2008 63 (Suppl. 88 85.
18. Ivan P, Dimitrov V, Gorine NM et al. Comparison of the efficacy and safety of bilastine 20mg versus desloratadine 5mg in seasonal allergic rhinitis patients. Allergy 2009 64 : 158 165.
19. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L et al. The Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009 39 : 1338 1347.
20. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy 2008 63 : 777 780.
21. Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
22. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004 93 : 142 146.
23. Audicana MT, Lecha M, Marquina A, Bressieux JM, Leynadier F, Valiente R. A double-blind, randomized, dose-ranging trial in four parallel groups of 10, 20, and 30 mg bilastine once daily vs placebo in the symptomatic treatment of chronic idiopathic urticaria (CU). J Investig Allergol Clin Immunol 2007 17 (Suppl. 3 77 (abstract).
24. Roupe K, Sologuren A, Crean C, Valiente R. Effects of age and gender on the pharmacokinetics and pharmacodynamics of bilastine. J Clin Pharmacol 2007 47 : 1198 (abstract 70).
25. Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007 8 : 37 42.
26. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D et al. Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003 48 : 535 541.
27. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001 40 : 72 76.
28. Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2005 94 : 662 669.
29. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000 84 : 517 522.
30. Finn AF Jr., Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999 104 : 1071 1078.
31. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006 45 : 469 474.
32. Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006 154 : 533 538.
33. Walsh GM. A review of the role of levocetirizine as an effective therapy for allergic disease. Expert Opin Pharmacother 2008 9 : 859 867.
34. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs 2004 64 : 523 561.
35. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002 32 : 489 498.
36. Simons FER, Simons KJ. H1 antihistamines. Current status and future directions. WAO J 2008 1 : 145 155.
37. Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: an internet survey on health behaviours, symptom patterns, and treatment needs in European adult patients. Br J Dermatol 2009 160 : 633 641.